tbuckley/cabot-search huggingface dataset:
Prognostic factors for long-term overall survival (OS) for patients (pts) undergoing first-line treatment for metastatic colorectal cancer (mCRC) with chemotherapy (CT) plus bevacizumab (bev): Findings from a large observational study.
Authors: Dirk Arnold, Wilfried Grothe, Dirk Tummes, Manfred Kindler, Volker Petersen, Stefanie Boszeit-Luft, Joerg Seraphin, Andreas Kutscheidt
Journal: Journal of Clinical Oncology (2012)

590 Background: Bev+CT has been shown to improve OS vs. CT alone in phase III and IV mCRC studies. However, as only a subset of pts experience OS &gt;30 months (m), clinical factors may help to identify pt groups with the largest potential benefit. Methods: This large observational study included pts receiving bev with various first-line CT regimens in Germany from 2005–2009, with predefined assessment of OS, progression free survival (PFS), toxicity and 22 baseline variables, including pt characteristics, pre-treatment duration/procedures, blood parameters, tumour characteristics. Pts with long-term OS (defined as OS &gt;30m) were compared to those with OS &lt;30m. Surviving pts with observations &lt;30m were defined as ‘censored’. Association between variables and OS was explored by univariate analyses and then multivariate analysis (logistic regression) to find independent variables for long-term OS. Results: 392 (22%) out of 1777 eligible pts had OS &gt;30m (195 events, median OS 46.8m), 717 pts (40%) had OS &lt;30m (median OS 14.3m), and 688 (38%) pts were censored. Median PFS was 17.7m (329 events) for pts with OS &gt;30m, 7.7m for pts with OS &lt;30m, and 11.8m (313 events) for censored pts. In the univariate analysis, nine variables were associated with OS &gt;30m: age (continuous variable; p=0.0008), ECOG PS (0 vs. 1–4; p=0.0025), WBC &lt;8.0/nL (p=0.013), CEA &lt;20ng/mL(p&lt;0.0001), single metastatic site (p&lt;0.0001), initial pT4 vs. others (p&lt;0.0001), pN0 vs. pN1/2 (p=0.0002), initial M0 vs. M1 (p=0.0021), grading G1/2 vs. G3/4 (p&lt;0.0001). Independent variables for pts with OS &lt;30m were found in the multivariate analysis. Conclusions: In general, the prognostic factors identifying long-term survivors in the CT only era are confirmed in this large cohort with bev treatment. However, the predominant role of grading and CEA level are remarkable. [Table: see text]
Prognostic Validation of Proposed BCLC-B Substaging System in Hepatocellular Carcinoma Patients Treated by Transarterial Chemoembolization
Authors: M. Biolato, G. Gallusi, M. Iavarone, G. Cabibbo, S. Racco, A.D. Santis, C. Della Corte, M. Maida, A.F. Attili, A. Sangiovanni, C. Cammà, G. La Torre, A. Gasbarrini, A. Grieco
Journal: Journal of Hepatology (2016)
P0554 : Hepatitis E virus infection induces an innate immune response in human chimeric mice
Authors: L. Allweiss, S. Gass, T. Volz, K. Giersch, J. Kah, A.W. Lohse, J. Petersen, S. Polywka, S. Pischke, M. Dandri, M. Lùtgehetmann
Journal: Journal of Hepatology (2015)
Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors
Authors: Aditya Bagrodia, Byron H. Lee, William Lee, Eugene K. Cha, John P. Sfakianos, Gopa Iyer, Eugene J. Pietzak, Sizhi Paul Gao, Emily C. Zabor, Irina Ostrovnaya, Samuel D. Kaffenberger, Aijazuddin Syed, Maria E. Arcila, Raju S. Chaganti, Ritika Kundra, Jana Eng, Joseph Hreiki, Vladimir Vacic, Kanika Arora, Dayna M. Oschwald, Michael F. Berger, Dean F. Bajorin, Manjit S. Bains, Nikolaus Schultz, Victor E. Reuter, Joel Sheinfeld, George J. Bosl, Hikmat A. Al-Ahmadie, David B. Solit, Darren R. Feldman
Journal: Journal of Clinical Oncology (2016)

Purpose Owing to its exquisite chemotherapy sensitivity, most patients with metastatic germ cell tumors (GCTs) are cured with cisplatin-based chemotherapy. However, up to 30% of patients with advanced GCT exhibit cisplatin resistance, which requires intensive salvage treatment, and have a 50% risk of cancer-related death. To identify a genetic basis for cisplatin resistance, we performed whole-exome and targeted sequencing of cisplatin-sensitive and cisplatin-resistant GCTs. Methods Men with GCT who received a cisplatin-containing chemotherapy regimen and had available tumor tissue were eligible to participate in this study. Whole-exome sequencing or targeted exon-capture-based sequencing was performed on 180 tumors. Patients were categorized as cisplatin sensitive or cisplatin resistant by using a combination of postchemotherapy parameters, including serum tumor marker levels, radiology, and pathology at surgical resection of residual disease. Results TP53 alterations were present exclusively in cisplatin-resistant tumors and were particularly prevalent among primary mediastinal nonseminomas (72%). TP53 pathway alterations including MDM2 amplifications were more common among patients with adverse clinical features, categorized as poor risk according to the International Germ Cell Cancer Collaborative Group (IGCCCG) model. Despite this association, TP53 and MDM2 alterations predicted adverse prognosis independent of the IGCCCG model. Actionable alterations, including novel RAC1 mutations, were detected in 55% of cisplatin-resistant GCTs. Conclusion In GCT, TP53 and MDM2 alterations were associated with cisplatin resistance and inferior outcomes, independent of the IGCCCG model. The finding of frequent TP53 alterations among mediastinal primary nonseminomas may explain the more frequent chemoresistance observed with this tumor subtype. A substantial portion of cisplatin-resistant GCTs harbor actionable alterations, which might respond to targeted therapies. Genomic profiling of patients with advanced GCT could improve current risk stratification and identify novel therapeutic approaches for patients with cisplatin-resistant disease.
Sézary Syndrome: Clinicopathological and Immunophenotypical Characteristics and Outcomes
Authors: Christa Roe, Jennifer Rock-Klotz, Elyce Turba, Christopher Rodriguez Salamanca, Janice Bennett, Farrah Farquharson, Sem Bastien, Barbara Williams, Rebecca Levy, Yibo Li, Michael Montejo, Ernesto Ayala, Pedro Horna, Lewis F Glass, Rami S. Komrokji, Lubomir Sokol
Journal: Blood (2015)
CML treated by low dose interferon alfa-2B vs hydroxyurea alone: interim report of a multicenter randomized trial
Authors: AC Louwagie, JC Kluin-Nelemans, A Delannoy, JF Van den Burgh, Marc Boogaerts, A Bosly, JL Michaux, P Zachee, Anne Hagemeijer-Hausman, Herman Van den Berghe
Journal: Blood (1995)
Biochemical correlates of fatigue in patients at a comprehensive cancer center.
Authors: A. A. Bharne, P. Mills, W. Bardwell, M. White, K. Messer, L. Bazhenova
Journal: Journal of Clinical Oncology (2010)

9162 Background: Cancer-related fatigue is a widely reported distressing symptom. We examined biochemical correlates of fatigue in patients with and without cancer at Moores UCSD Comprehensive Cancer Center (MCCC). Methods: All patients at first visit to MCCC complete a 39-question screen assessing problems including fatigue, sleep and mood disturbance on a 5-point scale (0=not a problem, 1=mild, 2=moderate, 3=severe, 4=very severe). We measured cortisol, IL-1B, IL-6, IL-8, neopterin, TNF- a, testosterone and tryptophan as potential biomarkers of fatigue in blood samples collected the same day for the MCCC biorepository. ANOVA was used to assess differences in mean concentration among 0, 1 and 2+ fatigue levels, overall and for cancer and non-cancer patients. Results: Overall, 118 (61%) of 195 [133 cancer and 62 non-cancer] patients reported problems with fatigue. There was no significant difference in the proportion of cancer (n=81 ; 61%) and non-cancer patients (n=37 ; 60%) reporting fatigue. Tryptophan (mM) increased with fatigue severity overall (p=0.05), from 24.66 in those without fatigue to 25.38 in those with mild fatigue and 29.46 in those with moderate to very severe fatigue. In cancer patients only, neopterin (nmol/L) increased with fatigue severity (p=0.05), from 7.03 in those without fatigue to 10.25 in those with mild fatigue and 12.61 in those with moderate to very severe fatigue. Some cytokines showed non-significant mean trends. TNF-a (pg/mL) increased with fatigue overall. In cancer patients, IL-6 (pg/mL) decreased with fatigue while in non-cancer patients, IL-8 (pg/mL) decreased with fatigue. No trends in mean levels were observed between fatigue and cortisol (in part because sampling time was not controlled), IL-1B or testosterone. Conclusions: Fatigue is prevalent among cancer and non-cancer patients. Tryptophan levels increased with fatigue in all patients, while neopterin levels increased with fatigue only in cancer patients. TNF-a, IL-6, and IL-8 suggested varying trends, but were not significant in this small sample. These results suggest possible biomarker roles for certain cytokines in monitoring fatigue and warrant further study. No significant financial relationships to disclose.
Assessment of Health-Related Quality of Life in Chronic Hepatitis B Infection Patients in Turkey: A Multicenter Study
Authors: Z. Karacaer, B. Cakir, H. Erdem, K. Ugurlu, G. Durmus, N.K. Ince, C. Ozturk, A. Batirel, E.M. Yilmaz, I. Bozkurt, M. Sunbul, A. Aynioglu, A. Atilla, A. Erbay, A. Inci, C. Kader, E.T. Tigen, G. Karaahmetoglu, S.A. Coskuner, E. Dik, H. Tarakci, S. Tosun, F. Korkmaz, S. Kölgelier, F.Y. Karadag, S. Erol, K. Turker, C. Necan, A.M. Sahin, P. Ergen, G. Iskender, P. Korkmaz, E.G. Eroglu, Y. Durdu, M. Ulug, S.S. Deniz, F. Koc, S.N. Alpat, N.O. Cuvalci, O. Evirgen, H. Sozen, M. Dogan, S. Kaya, M. Altindis, E. Aslan, R. Tekin, B.E. Sezer, K. Ozdemir, G. Ersoz, A. Sahin, I. Celik, E. Aydin, A. Bastug, R. Harman, H.D. Ozkaya, E. Parlak, I. Yavuz, S. Sacar, S. Comoglu, E. Yenilmez, F. Sirmatel, I.I. Balkan, Y. Alpay, M. Hatipoglu, A. Denk, G. Senol, M. Bitirgen, M.F. Geyik, R. Guner, A. Kadanali, A. Karakas, M. Namiduru, H. Udurgucu, R.P. Boluktas
Journal: Journal of Hepatology (2016)
AMD3100 Combined with Standard Doses of G-Csf Leads to Rapid, Consistent Mobilization of Hematopoietic Progenitor Cells in Patients with Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma.
Authors: Patrick Stiff, Ivana Micallef, Philip McCarthy, Margarida Magalhaes-Silverman, Neal Flomenberg, Daniel Weisdorf, Guido Tricot, Mary Territo, Rafat Abonour, Karin Badel, Gary Calandra
Journal: Blood (2004)
Induced Pluripotent Stem Cells (IPSCS) from a Patient with Familial Hypercholesterolemia: A Novel Model to Study LDL Receptor Functions and Targeted Recombination
Authors: J. Caron, S. Goulinet-Mainot, S. Saheb, E. Bruckert, A. Weber, T.H. Nguyen, A. Dubart-Kupperschmitt
Journal: Journal of Hepatology (2016)
Final SVR24 Data From the Phase 3 C-Edge Treatment-Naïve Study of Elbasvir (EBR)/Grazoprevir (GZR) in Patients with Chronic HCV Genotype 1, 4 or 6 Infection
Authors: S. Zeuzem, R. Ghalib, K.R. Reddy, P. Pockros, Z.B. Ari, Y. Zhao, D. Brown, M. DiNubile, M. Robertson, J. Wahl, E. Barr, J. Butterton, E. Martin
Journal: Journal of Hepatology (2016)
EARLY ONSET BODY WEIGHT LOSS DURING CONCURRENT CHEMO-RADIOTHERAPY FOR NON-SMALL CELL LUNG CANCER IS NOT DUE TO DYSPHAGIA OR REDUCED CALORIE INTAKE
Authors: Celine Op Den Kamp, Dirk De Ruysscher, Ruud Houben, Cary Oberije, Gerben P Bootsma, Wiel Geraedts, Cordula Pitz, Ramon Langen, Emiel Wouters, Anne-Marie Dingemans, Annemie Schols
Journal: Journal of Thoracic Oncology (2013)
Differential Reductions in Viral Antigens Expressed from CCCDNAVS Integrated DNA in Treatment Naïve HBEAG Positive and Negative Patients with Chronic HBV after RNA Interference Therapy with ARC-520
Authors: M.-F. Yuen, H.L.Y. Chan, K. Liu, B.D. Given, T. Schluep, J. Hamilton, C.-L. Lai, S.A. Locarnini, J.Y.N. Lau, C. Ferrari, R.G. Gish
Journal: Journal of Hepatology (2016)
Comparison of Daily Norfloxacin versus Weekly Ciprofloxacin for the Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients: A Randomized Controlled Trial
Authors: H.J. Yim, S.J. Suh, Y.K. Jung, S.Y. Yim, Y.S. Seo, S.Y. Park, J.Y. Jang, Y.S. Kim, H.S. Kim, B.I. Kim, S.H. Um
Journal: Journal of Hepatology (2016)
Novel Therapeutic Targets for Primary Sclerosing Cholangitis-Associated Biliary Tract Cancer Identified by Tissue Sequencing
Authors: B. Goeppert, T. Folseraas, S. Roessler, V. Endris, K. Grzyb, P. Milkiewicz, B. Gornicka, E. von Seth, A. Bergquist, A. Franke, T.J. Eide, K.M. Boberg, P. Schirmacher, T.H. Karlsen
Journal: Journal of Hepatology (2016)
Nonadherence to Oral 6-Mercaptopurine (6MP) in a Multi-Ethnic Cohort of Children with Acute Lymphoblastic Leukemia (ALL) and Its Impact On Relapse – a Children's Oncology Group (COG) Study (AALL03N1)
Authors: Smita Bhatia, Wendy Landier, Lindsey Hageman, Heeyoung Kim, Cara Hanby, Kornegay Nancy, Bruce C. Bostrom, Jacqueline Casillas, David S Dickens, Kelly W. Maloney, Leo Mascarenhas, Jane Meza, Arthur Kim Ritchey, Amanda M Termuhlen, William L. Carroll, F. Lennie Wong, Mary V. Relling
Journal: Blood (2012)
Secondary MDS/AML In Hodgkin Lymphoma Patients Treated within German Hodgkin Study Group (GHSG) Clinical Trials After Introduction of the BEACOPP Protocol
Authors: Dennis A. Eichenauer, Heinz Haverkamp, Karolin Behringer, Teresa Halbsguth, Michael Fuchs, Volker Diehl, Peter Borchmann, Andreas Engert
Journal: Blood (2010)
Study of cisplatin, etoposide, bleomycin, and escalating dose cyclophosphamide therapy for children with high-risk germ cell tumors: A Children's Oncology Group report
Authors: M. H. Malogolowkin, M. Krailo, L. A. Frazier, T. A. Olson
Journal: Journal of Clinical Oncology (2009)

10035 Background: In the intergroup high-risk germ cell tumors (HR-GCT) study (CCG-8882/POG-9049) patients with extragonadal GCT treated with high-dose cisplatin, etoposide, and bleomycin (HD-PEB) had a 2 year-EFS of 84% versus 74% for those treated with standard PEB (PEB), suggesting that treatment intensification might be beneficial. The goal of this study was to establish the maximum tolerated dose (MTD) and toxicity profile of cyclophosphamide combined with PEB in untreated patients with HR-GCT. Methods: From July 2004 to August 2007, 19 eligible children and adolescents with stage III/IV extragonadal GCT received cisplatin 20 mg/m 2 /day × 5, etoposide 100 mg/m 2 /d × 5, bleomycin 15 mg/m 2 on d1, and escalating doses of cyclophosphamide (1.2, 1.8 or 2.4 g/m 2 ) on d1. DLT was defined as any grade 4 non-hematologic toxicity other than nausea and vomiting, fever and infection, and any non-hematologic grade 3 toxicity which had not reversed (&lt; grade 2) within 28 days of treatment; or hematologic toxicity grade 3 or 4, which despite hematopoietic growth factor support, was not reversible within 28 days of treatment. Results: The toxicities reported were expected for this treatment regimen, protocol therapy was well tolerated and all 3 cyclophosphamide levels were feasible. Only 1 patient who had hyperglycemia was considered to have DLT by the institutional investigator. Fifteen of the 19 patients were removed from protocol therapy after 4 cycles of therapy; 11 were disease-free, 2 electively terminated protocol therapy, 1 patient was lost to follow-up, and 1 had progressive disease (PD). Four patients received 2 more cycles of C-PEB, of these 3 were disease-free and 1 had PD. The 2 year-EFS and OS were 71% (95% CI: 43–87%) and 88% (95% CI: 59–97%), respectively. Conclusions: The addition of cyclophosphamide to the standard PEB regimen is feasible and well tolerated at all dose levels used on this study. Due to the small sample size we cannot establish that the addition of cyclophosphamide to the standard PEB regimen is beneficial in increasing the EFS when compared to the standard PEB regimen. Further evaluation of this regimen is warranted. No significant financial relationships to disclose.
Flight: For Sophia
Authors: Brenda Butka
Journal: Annals of Internal Medicine (2016)

Ad Libitum20 September 2016Flight: For SophiaBrenda Butka, MDBrenda Butka, MDFrom Nashville, Tennessee.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M16-0922 Audio Reading - “Flight: For Sophia” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Flight: For Sophia," by B. Butka. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail the trees looked like fossilsexcavated in a slate sky,lace bones pressed in stone,on the morningthe girl named knowledgefinally ran out of breath.nerves stripped, muscleswatered downshe wrapped it up,gave it over, blinked yes and no and yes,the questiondichotomous, false, perhapsnot binary at all.we stood outsideembarrassed, relieved,fate arriving in this packetof ordinary words. we passed themback and forth.we wonder at the tiny wrist bones,fossils, trees, the marks that feathersleave behind.the girl named knowledgeflew awayleft nothing. Author, Article, and Disclosure InformationAffiliations: From Nashville, Tennessee.Current Author Address: Brenda Butka, MD; e-mail, brenda.[email protected]edu. PreviousarticleNextarticle Advertisement Audio Reading - “Flight: For Sophia” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Flight: For Sophia," by B. Butka. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 20 September 2016Volume 165, Issue 6Page: 456KeywordsBoneMusclesMuscular dystrophiesNerves ePublished: 20 September 2016 Issue Published: 20 September 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Targeted Proteomics Predicts Sustained Complete Response after Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma
Authors: S.J. Yu, H. Min, Y.Y. Cho, J.-J. Yoo, D.H. Lee, E.-J. Cho, J.-H. Lee, Y.J. Kim, C.Y. Kim, J.-H. Yoon, Y. Kim
Journal: Journal of Hepatology (2016)
S109 Effect of continued treatment with pirfenidone following a clinically meaningful decline in percent predicted forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF): Abstract S109 Table 1
Authors: PW Noble, C Albera, WZ Bradford, U Costabel, I Glaspole, MK Glassberg, L Lancaster, DJ Lederer, Z Lin, CA Pereira, JJ Swigris, D Valeyre, SD Nathan
Journal: Thorax (2015)

<h3>Introduction and objectives</h3> The clinical course in patients with IPF is characterised by substantial inter- and intra-subject variability in the rates of disease progression, thereby confounding clinical assessments of therapeutic responses in individual patients. We pooled data from three Phase 3 trials to assess the potential benefit of continued treatment with pirfenidone in patients who experienced a ≥10% decline in percent predicted forced vital capacity (%FVC) during the first 6 months of treatment. <h3>Methods</h3> Source data included all patients randomised to treatment with pirfenidone 2403 mg/d or placebo in the Phase 3 ASCEND or CAPACITY studies (N = 1247). We selected patients with a ≥10% absolute decline in%FVC by the month 3 or 6 study visit and compared the proportion of patients in the pirfenidone and placebo groups who experienced any of the following during the subsequent 6-month interval: (1) ≥10% absolute decline in%FVC or death; (2) no further decline in%FVC; or (3) death. Observed data were used in the analysis. <h3>Results</h3> 34 (5.5%) and 68 (10.9%) patients in the pooled pirfenidone and placebo groups, respectively, experienced a ≥10% absolute decline in%FVC between baseline and month 6 (relative difference, 49.5%). Analysis of outcomes during the subsequent 6-month interval demonstrated that fewer patients in the pirfenidone group compared with placebo experienced a ≥10% decline in%FVC or death (pirfenidone, 2/34 [5.9%] vs. placebo, 19/68 [27.9%]). More patients in the pirfenidone group compared with placebo had no further decline in%FVC (20/34 [58.8%] vs. 26/68 [38.2%]; Table 1). Additionally, there were fewer deaths in the pirfenidone group (1/34 [2.9%]) compared with placebo (14/68 [20.6%]). <h3>Conclusions</h3> Among patients who experienced a ≥10% decline in%FVC during the first 6 months of treatment, continued treatment with pirfenidone resulted in a lower risk of%FVC decline or death during the subsequent 6 months. These findings suggest a potential benefit to continued treatment with pirfenidone despite an initial decline in FVC.
Validating Molecular Targets of Thalidomide in CLL: Net Effect of Increased Apoptosis through the Intrinsic Pathway and down Regulation of NF-kB Signaling- Validation Using Gene Expression Profile from the Phase I/II Clinical Trial of Thalidomide and Fludarabine.
Authors: Asher Alban Chanan-Khan, Swaminathan Padmanabhan, Leighton Stein, Jennifer Panzarella, Kena C. Miller, Leslie Hawthorne
Journal: Blood (2005)
Low Percent of Granzyme B Positive T-Regulatory Cells (CD4+CD25high) As a Predictor of Acute Graft-Versus-Host Disease (GVHD) after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
Authors: Mikhail Drokov, Elena N. Parovichnikova, Larisa A Kuzmina, Irina Galtseva, Vera Vasilieva, Valeri G. Savchenko
Journal: Blood (2014)
A 2-Part Phase I Study in Patients with Solid or Hematologic Malignancies: Dose Proportionality of Subcutaneous (SC) Azacitidine (AZA) and Pharmacokinetics of SC AZA in Patients with Severe Renal Impairment,
Authors: Eric Laille, Alain C. Mita, Sanjay Goel, Nashat Y. Gabrail, Joseph Schwarz, CL Beach
Journal: Blood (2011)
Percutaneous Electrochemotherapy of Malignant Main Portal Veins Thrombosis: A Prospective Case Series
Authors: L. Tarantino, G. Busto, A. Nasto, R. Fristachi, L. Cacace, M. Talamo, P. Ambrosino, P. Gallo, P. Tarantino, C. Accardo
Journal: Journal of Hepatology (2016)
Temporal and Regional Differences in Therapy for Reinfarction Following Thrombolysis: Results from GUSTO I and ASSENT II
Authors: M Hudson, GI Barbash, CB Granger, Y Birnbaum, Katrijn Houbracken, KS Pieper, EM Ohman, EJ Topol, RM Califf, Frans Van de Werf
Journal: Journal of the American College of Cardiology (2000)
Response to Bortezomib Therapy for Multiple Myeloma (MM) in Actual Clinical Practice: Preliminary Effectiveness Findings of an International Observational Study.
Authors: Michel Delforge, Eirini Katodritou, Konstantinos Zervas, Deniz Sargin, Cyrille Hulin, Mats Linderholm, Evgenia Verrou, Vicki Poon, Ravinder Dhawan
Journal: Blood (2007)